Events

This is a promotional website intended for healthcare professionals in the UK and Ireland only.
Back to Events

5th July 2023 6:00PM BST - Virtual

Real world experience treating WM and what’s next for CLL

This promotional meeting, sponsored by BeiGene, brought together a group of clinical experts to discuss their experience of treating patients with Waldenstrom’s Macroglobulinaemia using BRUKINSA®▼ (zanubrutinib), a next generation BTK inhibitor. This meeting involved sharing case studies and discussing the role of BRUKINSA in treatment pathways and hospital protocols. The second part of the meeting focused on the role of BRUKINSA (zanubrutinib) in treating Chronic Lymphocytic Leukaemia (CLL).

Agenda

Recordings

Welcome to “Real world experience treating WM and what’s next for CLL” – Dr Robert Mulrooney

Date of preparation: July 2023. 0723-BRU-PRC-076

Waldenström’s macroglobulinaemia/ lymphoplasmacytic lymphoma: An introduction – Prof George Follows

Date of preparation: July 2023. 0723-BRU-PRC-077

Case-based panel discussion – Dr Pam McKay

Date of preparation: July 2023. 0723-BRU-PRC-078

Case-based panel discussion – Dr Sarah Lawless

Date of preparation: July 2023. 0723-BRU-PRC-079

Case-based panel discussion – Dr Vishal Jayakar

Date of preparation: July 2023. 0723-BRU-PRC-080

BTK inhibitor choices in CLL: What’s next for zanubrutinib in CLL? – Dr Toby Eyre

Date of preparation: July 2023. 0723-BRU-PRC-081

Closing


Date of preparation: July 2023. 0723-BRU-PRC-082

Speakers

Prof George Follows

Addenbrooks Hospital

He is a former chair of the UK CLL Forum and CLL Guidelines Panel and Research Lead for haematology clinical trials at the Cambridge Cancer Trials Centre. He currently chairs the UK Hodgkin Lymphoma Guidelines Panel and is an Associate Professor affiliated to the University of Cambridge Department of Haematology.

Dr Pam McKay

Beatson West of Scotland Cancer Centre

Dr McKay is a Consultant Haematologist at the Beatson, West of Scotland Cancer Centre and an Honorary Clinical Associate Professor at the University of Glasgow School of Medicine. She has a specialist interest in lymphoma and is actively involved in lymphoma at a regional and national level. She is currently a member of the NCRI Lymphoma Clinical Studies Group and the high-grade lymphoma and Hodgkin’s lymphoma Clinical Studies Subgroups.

Dr Toby Eyre

Oxford University Hospitals NHS Foundation Trust

Dr Toby Eyre is a consultant haematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is an expert in the management of patients with lymphoma and patients with chronic lymphocytic leukaemia. ​He is the current BSH-NIHR Researcher of the year in 2021 and an Associate Editor at the British Journal of Haematology.

Dr Sarah Lawless

Belfast City Hospital

Dr Lawless specialises in lymphoma, myeloma and haematopoietic stem cell transplantation. Dr Lawless began her career in haematology at BCH in 2008 and she currently holds the position of speciality improvement and SACT lead at Belfast City Hospital. She is actively involved in clinical trials and is a member of UK NCRI group and is the invited regional N. Ireland representative on the UK Myeloma Society executive committee.

Dr Vishal Jayakar

Kingston Hospital NHS Foundation Trust

After completing his medical education and postgraduate training in internal medicine from King Edward Memorial Hospital in Mumbai, India with 7 distinctions, Dr Jayakar did haematology SHO jobs at UCL and Royal Marsden, London whilst acquiring his MRCP qualification. He has been a Consultant Haematologist at Kingston Hospital, London since 2011. He also co-organises the venerable Imperial Morphology Courses with Prof Barbara Bain and has a honorary lecturer contract at Imperial College, London.

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

September 2023 [0823-BRU-PRC-180]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not